Antibody test launch KSL Diagnostics recently launched a first-of-its-kind antibody test to assess individual immune response to COVID-19 and infection risk upon exposure, presenting an opportunity to position complementary immunology and serology services to healthcare providers and payers.

National reference lab As a national reference laboratory headquartered near Buffalo, KSL has a scalable platform for high-complexity testing and collaboration with pathologists and clinicians, enabling partnerships for expanding test menu, reference workflows, and multi-site deployments.

Moderate revenue With reported revenue in the mid six figures to low seven figures range, there is potential to upsell expanded diagnostic panels, contract research services, and managed testing programs to lab networks, hospitals, and academic medical centers.

Tech-enabled ops Utilizing Google Cloud, Sentry, Microsoft 365, and web platforms, KSL’s tech stack supports scalable testing operations, data management, and regulatory-compliant user experiences—a selling point for integrated IT-enabled lab solutions and secure data sharing.

Growth-ready niche Small to mid-size team size combined with growth ambitions and alignment to immunology and oncology applications positions KSL as a target for partnerships with larger CROs, specialty labs, and gene/diagnostics companies seeking collaboration on novel diagnostics and therapeutic applications.